Vivos Therapeutics (VVOS) Non Operating Interest Expenses (2020 - 2022)

Vivos Therapeutics (VVOS) has reported Non Operating Interest Expenses for 3 consecutive years, with $36000.0 the latest figure, recorded in Q3 2022.

• On a quarterly basis, Non Operating Interest Expenses rose 300.0% year-over-year to $36000.0 in Q3 2022; TTM through Sep 2022 was $115000.0, a 307.54% increase from a year earlier, with the FY2021 full-year figure at $14000.0, down 85.42% from the prior year.
• Non Operating Interest Expenses was $36000.0 for Q3 2022 at Vivos Therapeutics, down from $37000.0 in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $43723.0 in Q1 2020 and troughed at $1000.0 in Q1 2021.
• A 3-year average of $20181.8 and a median of $17218.0 in 2020 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses sank 97.71% in 2021 and surged 3700.0% in 2022, its largest moves.
• Over 3 years, Non Operating Interest Expenses stood at $17218.0 in 2020, then slumped by 76.77% to $4000.0 in 2021, then soared by 800.0% to $36000.0 in 2022.
• The last three Non Operating Interest Expenses figures came in at $36000.0 (Q3 2022), $37000.0 (Q2 2022), and $38000.0 (Q1 2022), per Business Quant data.